Drugs / cell-free stem cell-derived extract
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04971798 | Jan 2023 → Dec 2025 | osteoarthritis, knee | General Therapeutics | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cell-free stem cell-derived extract | “The proposed study aims to evaluate the safety and efficacy of intraarticular injection of the novel cell-free stem cell-derived extract (CCM) for the treatment of knee OA.” PMID 34416898 ↗ Aug 2021 |
| Known as | CCM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04971798 ↗ |
| Modality | Other / unclassified | “We formulated a novel cell-free stem cell-derived extract (CCM) from human progenitor endothelial stem cells (hPESCs).” PMID 34416898 ↗ Aug 2021 |
| Route | Other | “Intraarticular injection” NCT04971798 ↗ |